Brief: Irlab Is Granted Patent Strengthening Market Exclusivity Of Drug Candidate Mesdopetam In China
04/09/2025 06:06
Sept 4 (Reuters) - IRLAB Therapeutics AB IRLABa.ST: IRLAB IS GRANTED A PATENT STRENGTHENING THE MARKET EXCLUSIVITY OF THE DRUG CANDIDATE MESDOPETAM IN CHINA NEWLY GRANTED PATENT COVERS SALT FORM OF DRUG USED IN ONGOING CLINICAL DEVELOPMENT AND EXPIRES IN 2040S IN EVENT OF A POSSIBLE EXTENSION OF PATENT PERIOD (PATENT TERM EXTENSION; PTE), EXCLUSIVITY COULD POTENTIALLY EXTEND TOWARDS MID 2040S. Source text: ID:nMFN6KrF9S Further company coverage: [IRLABa.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))